OZEMPIC and vulvar symptoms

What the labels say

An approved label is the one document that has to list what a drug did in its trials, with rates and a placebo column. Both semaglutide labels were searched for vulvar, vulvovaginal, vaginal, genital and labial terms. Neither one lists a reaction of that kind anywhere: not in WEGOVY’s table of 19 reactions reported in at least 2% of patients, not in OZEMPIC’s list of the five reported in at least 5%, and not in its list of the five below that threshold.^1,2

That is a finding rather than a gap, and it has a limit worth stating. A label reports what was reported in its trials; something that was not reported often enough, or not asked about, does not appear. The tables for both products are on the WEGOVY side effects page and the OZEMPIC one.

What the reporting system holds

FDA runs a database of adverse events that patients, clinicians and companies report after a drug is on the market. It is searchable, and it is the only place where a question like this one has any numbers at all attached to it.

Read against the same database’s 10,677 reports of nausea, the vulvovaginal terms are rare in the reports. Read on its own, 95 reports is 95 people who described something. Both sentences are true, and neither one says the drug caused it.³

What has not been measured

A search of the published literature on 12 September 2026 found nothing that measured genital tissue in people taking semaglutide or another GLP-1 drug. Pairing semaglutide and GLP-1 receptor agonists with vulvar, vulvovaginal and genital terms returned reviews, case work and animal studies about other organs. A narrower search, for labia majora volume, atrophy or laxity alongside weight loss, returned no records at all.

The explanation people are usually offered is that rapid fat loss changes the fat pads of the labia majora, as it changes them elsewhere. That is an assumption rather than a measurement, and this site does not publish it as a finding. The only volume change of this kind that has been measured in work this site holds is in the face: a study of 20 patients found a median 9% fall in midface volume alongside the weight, which is on the Ozempic face page. Nobody has run the equivalent study anywhere else on the body.⁴ The facial-change evidence review explains what that small study actually measured.

What is documented, and might matter to the same reader

Two things on the labels are real and are worth knowing, without pretending they connect to a symptom nobody has studied. The first is that vomiting and diarrhea are common on these drugs, and how often diarrhea was reported and how long a bout ran is set out with its placebo column. The second is that both labels carry a warning about acute kidney injury from volume depletion, which is what dehydration does. Fluid balance is documented; what it has to do with vulvar dryness is not.^1,2

The other documented thing is weight. How fast the weight came off in the WEGOVY trials is measured week by week, and the body changes as it happens. Where and how it changes below the waist is, again, unmeasured.

If you have a symptom

If you do go, two facts from this page are useful to bring: the labels list no reaction of this kind, and the reporting system holds a small number of reports that nobody has confirmed. That is the whole of what is known, and it is more useful to a clinician than a headline is.

Questions